| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 673 | 1.430 | 1.316 | 1.096 | 896 | 282 | 0 | 0 | 0 | 543 |
| Total Income - EUR | 673 | 1.430 | 1.316 | 1.096 | 896 | 282 | 1.314 | 0 | 0 | 543 |
| Total Expenses - EUR | 2.942 | 1.423 | 690 | 1.095 | 928 | 605 | 1.743 | 12 | 44 | 46 |
| Gross Profit/Loss - EUR | -2.270 | 6 | 626 | 1 | -32 | -323 | -429 | -12 | -44 | 497 |
| Net Profit/Loss - EUR | -2.290 | -37 | 586 | -32 | -59 | -331 | -469 | -12 | -44 | 418 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Alesor Rx S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.507 | 3.103 | 2.688 | 2.283 | 1.891 | 1.513 | 0 | 0 | 0 | 0 |
| Current Assets | 22 | 3 | 22 | 364 | 154 | 388 | 178 | 166 | 52 | 450 |
| Inventories | 0 | 0 | 0 | 0 | 72 | 70 | 69 | 69 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Cash | 22 | 3 | 22 | 364 | 82 | 318 | 109 | 97 | 52 | 447 |
| Shareholders Funds | -2.359 | -2.371 | -1.745 | -1.745 | -1.770 | -2.067 | -2.489 | -2.509 | -2.546 | -2.113 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 5.889 | 5.478 | 4.455 | 4.392 | 3.814 | 3.968 | 2.667 | 2.675 | 2.598 | 2.564 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "9610 - 9610" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Alesor Rx S.r.l.